Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Paraben. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.94 |
| ▸ | CA1 | P00915 | 3/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | CA3 | P07451 | 1/20 | 0.94 |
| ▸ | TYR | P14679 | 1/20 | 0.94 |
| ▸ | DRD1 | P21728 | 1/20 | 0.94 |
| ▸ | CA4 | P22748 | 1/20 | 0.94 |
| ▸ | CA6 | P23280 | 1/20 | 0.94 |
| ▸ | CA5A | P35218 | 1/20 | 0.94 |
| ▸ | CA7 | P43166 | 1/20 | 0.94 |
| ▸ | CA9 | Q16790 | 1/20 | 0.94 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.94 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.94 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.80 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paraben SCHEMBL1756156 | 1.00 | CA2 (0.94) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL7622776 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Terephthalic Acid SCHEMBL6692916 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL20500516 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL5311518 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Terephthalic Acid SCHEMBL3460105 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL3212865 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL4110 | 0.97 | CA2 (1.00) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL15948949 | 0.95 | CA2 (0.84) | CA2CA1CA12CA3TYR | |
| Paraben SCHEMBL15948950 | 0.95 | CA2 (0.84) | CA2CA1CA12CA3TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104628677-A | Crystal forms of vortioxetine organic acid salt and preparation method thereof | UNIV ZHEJIANG | 2015-05-20 | — | — | CN | claimed |
| US-20130217911-A1 | Method For Producing Acyloxy Benzoic Acids | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-08-22 | — | — | US | claimed |
| EP-0637587-B1 | Bicyclic beta-lactam/paraben complexes | LILLY CO ELI (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0637587-A1 | Bicyclic beta-lactam/paraben complexes | ELI LILLY AND COMPANY (US) | 1995-02-08 | — | — | EP | claimed |
| US-20250283016-A1 | Polypeptides Having Beta-Glucanase Activity, Polynucleotides Encoding Same and Uses Thereof In Cleaning and Detergent Compositions | NOVOZYMES A/S (DK) | 2025-09-11 | — | — | US | disclosed |
| CN-113785039-B | Polypeptides having beta-glucanase activity, polynucleotides encoding same and use thereof in cleaning and detergent compositions | 诺维信公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20220169953-A1 | POLYPEPTIDES HAVING BETA-GLUCANASE ACTIVITY, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN CLEANING AND DETERGENT COMPOSITIONS | NOVOZYMES A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| CN-113785039-A | Polypeptides having beta-glucanase activity, polynucleotides encoding same and use thereof in cleaning and detergent compositions | 诺维信公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2021033729-A1 | SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR | 小野薬品工業株式会社 | 2021-02-25 | — | — | WO | disclosed |
| US-9173391-B2 | Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides | BASF SE (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-1614673-B1 | CRYSTAL OF p-HYDROXYBENZOIC ACID AND PROCESS FOR PRODUCING THE SAME | UENO FINE CHEMICAL IND (JP) | 2015-10-28 | — | — | EP | disclosed |
| CN-104628677-A | Crystal forms of vortioxetine organic acid salt and preparation method thereof | UNIV ZHEJIANG | 2015-05-20 | — | — | CN | disclosed |
| US-20020098518-A1 | Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state | LEVINSON DOUGLAS (US) | 2002-07-25 | — | — | US | disclosed |
| WO-2002044730-A1 | RAPID IDENTIFICATION OF CONDITIONS, COMPOUNDS, OR COMPOSITIONS THAT INHIBIT, PREVENT, INDUCE, MODIFY, OR REVERSE TRANSITIONS OF PHYSICAL STATE | TRANSFORM PHARMACEUTICALS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020048610-A1 | High-throughput formation, identification, and analysis of diverse solid-forms | MILLENNIUM PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051919-A9 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS INC (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001051919-A2 | HIGH-THROUGHPUT FORMATION, IDENTIFICATION, AND ANALYSIS OF DIVERSE SOLID-FORMS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0910249-A1 | RECTAL PLUG AND METHOD OF INTRODUCING SAME INTO A SLAUGHTERED ANIMAL | StarchTech, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0910249-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| WO-1996037110-A1 | RECTAL PLUG AND METHOD OF INTRODUCING SAME INTO A SLAUGHTERED ANIMAL | ANDERBERG STEVEN L (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217911-A1 | Method For Producing Acyloxy Benzoic Acids | ACOX1, PAH, FAAH | ESR1 749/4885ESR2 1492/4885CA2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.